Updates on Kinase Inhibitors in Allergy

Kinase inhibitors are emerging as transformative therapeutic agents in allergy. Advances in drug design have produced highly selective inhibitors with improved safety and efficacy, extending their clinical use beyond oncologic indications to the treatment of immune-mediated and hypersensitivity disorders. Bruton's tyrosine kinase inhibitors offer rapid, on-demand control of IgE-mediated reactivity and are approved for use in chronic urticaria. Janus kinase inhibitors demonstrate potent anti-inflammatory and anti-pruritic effects in atopic dermatitis and may expand into other chronic itch disorders. KIT inhibitors, both mutant- and wild type-specific, are redefining treatment possibilities for mastocytosis and chronic urticaria through mast cell suppression. This review highlights recent progress in the development and application of these drugs in allergic diseases. We summarize the mechanistic rationale for targeting each pathway, review pivotal clinical trial findings, and discuss safety profiles and practical considerations for clinical use. Collectively, these inhibitors are important additions to the therapeutic options in immune-mediated disorders.